Verona Pharma (VRNA) Competitors $58.30 -0.17 (-0.29%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRNA vs. TEVA, ITCI, SMMT, GMAB, RDY, MRNA, VTRS, QGEN, ASND, and ROIVShould you be buying Verona Pharma stock or one of its competitors? The main competitors of Verona Pharma include Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Verona Pharma vs. Teva Pharmaceutical Industries Intra-Cellular Therapies Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Moderna Viatris Qiagen Ascendis Pharma A/S Roivant Sciences Teva Pharmaceutical Industries (NYSE:TEVA) and Verona Pharma (NASDAQ:VRNA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk. Do analysts prefer TEVA or VRNA? Teva Pharmaceutical Industries presently has a consensus price target of $23.43, suggesting a potential upside of 74.84%. Verona Pharma has a consensus price target of $74.67, suggesting a potential upside of 28.40%. Given Teva Pharmaceutical Industries' higher possible upside, equities research analysts plainly believe Teva Pharmaceutical Industries is more favorable than Verona Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Verona Pharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Which has stronger earnings & valuation, TEVA or VRNA? Verona Pharma has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Verona Pharma is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.54B0.92-$1.64B-$1.45-9.24Verona Pharma$42.28M111.16-$54.37M-$2.16-26.92 Which has more risk and volatility, TEVA or VRNA? Teva Pharmaceutical Industries has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500. Is TEVA or VRNA more profitable? Verona Pharma has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Verona Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-9.91% 42.46% 6.65% Verona Pharma N/A -79.54%-43.49% Does the MarketBeat Community prefer TEVA or VRNA? Teva Pharmaceutical Industries received 1003 more outperform votes than Verona Pharma when rated by MarketBeat users. However, 80.73% of users gave Verona Pharma an outperform vote while only 67.82% of users gave Teva Pharmaceutical Industries an outperform vote. CompanyUnderperformOutperformTeva Pharmaceutical IndustriesOutperform Votes133467.82% Underperform Votes63332.18% Verona PharmaOutperform Votes33180.73% Underperform Votes7919.27% Does the media refer more to TEVA or VRNA? In the previous week, Teva Pharmaceutical Industries had 13 more articles in the media than Verona Pharma. MarketBeat recorded 19 mentions for Teva Pharmaceutical Industries and 6 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 1.55 beat Teva Pharmaceutical Industries' score of 1.13 indicating that Verona Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 14 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verona Pharma 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do institutionals & insiders believe in TEVA or VRNA? 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 85.9% of Verona Pharma shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 4.8% of Verona Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryTeva Pharmaceutical Industries beats Verona Pharma on 10 of the 19 factors compared between the two stocks. Remove Ads Get Verona Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRNA vs. The Competition Export to ExcelMetricVerona PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.70B$6.31B$5.33B$7.45BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-30.296.7621.7417.79Price / Sales111.16223.84371.9593.87Price / CashN/A65.6738.1534.64Price / Book18.765.826.403.98Net Income-$54.37M$142.25M$3.20B$247.46M7 Day Performance0.41%3.50%2.19%1.15%1 Month Performance-5.28%-13.41%-9.07%-6.52%1 Year Performance258.95%-11.92%9.89%0.20% Verona Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRNAVerona Pharma2.9107 of 5 stars$58.30-0.3%$74.67+28.1%+270.1%$4.71B$42.28M-30.3630Positive NewsGap DownTEVATeva Pharmaceutical Industries3.0275 of 5 stars$13.91+0.8%$23.43+68.5%+2.7%$15.77B$16.54B-9.5936,800Analyst DowngradeOptions VolumePositive NewsITCIIntra-Cellular Therapies3.4908 of 5 stars$131.87flat$106.23-19.4%N/A$14.05B$680.50M-151.57560Analyst ForecastPositive NewsSMMTSummit Therapeutics2.464 of 5 stars$17.32-0.2%$35.40+104.4%+573.6%$12.78B$700,000.00-61.85110News CoverageGap DownGMABGenmab A/S4.2023 of 5 stars$18.19-1.1%$41.33+127.2%-33.9%$12.04B$21.53B10.451,660Short Interest ↓Analyst RevisionNews CoverageGap DownHigh Trading VolumeRDYDr. Reddy's Laboratories3.2063 of 5 stars$12.59+1.8%$17.00+35.1%-6.3%$10.51B$311.31B20.0424,800Positive NewsHigh Trading VolumeMRNAModerna4.249 of 5 stars$25.64+2.1%$59.00+130.1%-74.7%$9.91B$3.20B-2.763,900Positive NewsVTRSViatris2.9692 of 5 stars$7.61-0.1%$10.50+38.0%-33.9%$9.08B$14.74B-10.2837,000High Trading VolumeQGENQiagen3.3623 of 5 stars$40.33+5.4%$47.71+18.3%+7.7%$8.96B$1.98B112.296,030High Trading VolumeASNDAscendis Pharma A/S3.113 of 5 stars$140.14-1.8%$204.64+46.0%+6.0%$8.50B$363.64M-19.741,017Analyst ForecastPositive NewsROIVRoivant Sciences2.6168 of 5 stars$9.26-2.1%$17.50+89.0%-7.2%$6.61B$122.59M-61.73860Positive NewsGap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies TEVA Alternatives ITCI Alternatives SMMT Alternatives GMAB Alternatives RDY Alternatives MRNA Alternatives VTRS Alternatives QGEN Alternatives ASND Alternatives ROIV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRNA) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
